Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Short-term Investments (2016 - 2025)

Historic Short-term Investments for AC Immune (ACIU) over the last 8 years, with Q3 2025 value amounting to $100.9 million.

  • AC Immune's Short-term Investments fell 3032.08% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.9 million, marking a year-over-year decrease of 3032.08%. This contributed to the annual value of $147.5 million for FY2024, which is 9946.71% down from last year.
  • AC Immune's Short-term Investments amounted to $100.9 million in Q3 2025, which was down 3032.08% from $122.5 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Short-term Investments registered a high of $125.8 billion during Q4 2021, and its lowest value of -$32.9 million during Q2 2021.
  • Moreover, its 5-year median value for Short-term Investments was $100.9 million (2025), whereas its average is $11.9 billion.
  • The largest annual percentage gain for AC Immune's Short-term Investments in the last 5 years was 37899751.7% (2021), contrasted with its biggest fall of 41700.75% (2021).
  • Quarter analysis of 5 years shows AC Immune's Short-term Investments stood at $125.8 billion in 2021, then tumbled by 99.92% to $94.5 million in 2022, then surged by 29204.54% to $27.7 billion in 2023, then plummeted by 99.47% to $147.5 million in 2024, then tumbled by 31.58% to $100.9 million in 2025.
  • Its Short-term Investments stands at $100.9 million for Q3 2025, versus $122.5 million for Q2 2025 and $139.8 million for Q1 2025.